de Vries Schultink AHM, et al. - Researchers compared the docetaxel exposure in docetaxel treated metastatic castration-resistant prostate cancer (mCRPC) patients vs patients with other solid tumors treated similarly in this meta-analysis. In addition, they compared patients with mCRPC vs other solid tumors in a clinical cohort regarding the incidence of neutropenia and described potential clinical consequences. As per logistic regression performed with 812 patients, a 2.2-fold lower likelihood of developing grade 3/4 neutropenia was observed in patients with mCRPC vs patients with other solid tumors. This suggests a lower risk of experiencing severe neutropenia, which may be ascribed to lower systemic exposure to docetaxel in mCRPC patients.